FBIO Fortress Biotech Inc.

4.41
-0.02  -0%
Previous Close 4.43
Open 4.43
Price To book 3.08
Market Cap 222826734
Shares 50,527,604
Volume 69,709
Short Ratio 10.71
Av. Daily Volume 155,983

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 2H 2017.
CAEL‐101
AL amyloidosis
Phase 2 data in adults due 1H 2019.
CEVA101
Severe Traumatic Brain Injury
Phase 2 data in children due 1H 2018.
CEVA101
Severe Traumatic Brain Injury
Phase 2 data due 1H 2018.
Pepvax vaccine
Cytomegalovirus (CMV)
Phase 1/2 initiated October 2016.
CK‐101
Solid tumors - cancer
Phase 2 trial ongoing with Phase 3 to be initiated in 2017.
N-acetyl-D-mannosamine (ManNAc)
GNE Myopathy
Phase 3 initiation announced September 27, 2017 with data due 2Q 2018.
IV Tramadol
Post-operative Pain

Latest News

  1. Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma
  2. ETFs with exposure to Fortress Biotech, Inc. : October 9, 2017
  3. Fortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
  4. Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301
  5. Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
  6. Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference
  7. Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
  8. Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer
  9. Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
  10. Fortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
  11. Mustang Bio to Present at the CAR-TCR Summit 2017
  12. Mustang Bio Commences Trading on the NASDAQ Global Market
  13. Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer)
  14. Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments for Complement-Mediated Diseases
  15. Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
  16. Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
  17. Fortress Biotech reports 2Q loss
  18. Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
  19. Checkpoint (CKPT): An Innovator of Immune-Enhanced Combination Therapies in Solid Tumors